Study Stopped
COVID precautions prevented enrollment of healthy controls, funding ended.
Glucose Homeostasis in Pseudohypoparathyroidism
Glucose Homeostasis and Beta Cell Function in Pseudohypoparathyroidism
1 other identifier
observational
14
1 country
1
Brief Summary
It is increasingly recognized that Pseudohypoparathyroidism type 1A (PHP1A) is associated with an increased risk of type 2 diabetes but the mechanism is unknown. In this pilot study we will assess β-cell function in patients with PHP1A and pseudopseudohypoparathyroidism PPHP.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Jun 2019
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
November 29, 2018
CompletedFirst Posted
Study publicly available on registry
December 3, 2018
CompletedStudy Start
First participant enrolled
June 19, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 30, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
April 30, 2021
CompletedMay 4, 2026
April 1, 2026
1.9 years
November 29, 2018
April 27, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
Insulin sensitivity (Si)
baseline
Study Arms (3)
Pseudphypoparathyroidism type 1A (PHP1A)
Case
Pseudopseudohypoparathyroidism (PPHP)
Case
Controls
Matched control group
Eligibility Criteria
Patients with PHP1A/PPHP and matched controls
You may qualify if:
- Diagnosis of PHP1A/PPHP
- Age between 6 and 50 years old
- Controls will be matched based on:
- Gender
- Race
- Age (±2 years if \<25 years old or ±5 years if ≥25 years old)
- BMI (±2 kg/m2)
- Diabetes status
You may not qualify if:
- Treatment with appetite-altering drug or initiation of a new weight loss program in the past 3 months
- Type 1 diabetes
- Type 2 diabetes treated with insulin or GLP-1 receptor agonists or A1c \>9%at their most recent clinic visit
- Pregnant or lactating women
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Vanderbilt University Medical Center
Nashville, Tennessee, 37212, United States
Related Publications (1)
Perez KM, Curley KL, Slaughter JC, Shoemaker AH. Glucose Homeostasis and Energy Balance in Children With Pseudohypoparathyroidism. J Clin Endocrinol Metab. 2018 Nov 1;103(11):4265-4274. doi: 10.1210/jc.2018-01067.
PMID: 30085125BACKGROUND
Related Links
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Ashley H Shoemaker, MD
Vanderbilt University Medical Center
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Associate Professor of Pediatrics
Study Record Dates
First Submitted
November 29, 2018
First Posted
December 3, 2018
Study Start
June 19, 2019
Primary Completion
April 30, 2021
Study Completion
April 30, 2021
Last Updated
May 4, 2026
Record last verified: 2026-04
Data Sharing
- IPD Sharing
- Will not share